SOURCE: StockCall


October 19, 2010 08:38 ET

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Makers Looking Good

JOHANNESBURG, SOUTH AFRICA--(Marketwire - October 19, 2010) - offers investors comprehensive research on the drugs - generic industry and has completed analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at to have free access to these researches. 

Generic drug companies stand to experience a very exciting time over the next few years, as patents for many of the top grossing brand name drugs are expiring. With patents expiring for branded drugs such as Cozaar and Hyzaar whose combined yearly sales crossed the $1 billion dollar mark last year, the opportunity for increased generic sales is up. Drug-maker Mylan Inc. has finally the right to market and sell generic version of Merck and Co.'s branded drugs Cozaar and Hyzaar. Additionally, Watson Pharmaceuticals Inc. has also received FDA approval for generic versions of Lotrel, another drug with huge sales figures. Watson Pharmaceuticals Inc. and Mylan Inc. research reports are available for free by signing up now at or is an online platform where investors doing their due-diligence on the drugs - generic industry can have easy and free access to our analyst research and opinions on Mylan Inc. and Watson Pharmaceuticals Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

While the release of patented drugs is beneficial to generic makers, it can prove devastating to the companies that originally create them. When exclusive sales rights expire, branded companies generally see a large decline in revenues and profits. This has prompted some companies in the branded drug market to start investing in the generic markets themselves. Register now at to have free access to our reports on the drugs - generic industry.

Branded companies are launching or acquiring generic businesses and selling generic versions of other top company products whose patents have expired. It is an interesting move and one that will certainly make competition in the generic sector more intense. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.  

Contact Information